Therapeutic potential of PACAP for neurodegenerative diseases

Cellular and Molecular Biology Letters

Volumn 20, Issue 2, 2015, Pages 265-278

  Yang, Rongqiang ^a   Jiang, Xin ^b   Ji, Rui ^a   Meng, Lingbin ^a   Liu, Fuli ^c   Chen, Xiaolei ^d   Xin, Ying ^e  

^a University of Louisville School of Medicine   (United States)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d Dartmouth College   (United States)

^e JILIN UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Neurodegenerative diseases; Neuroprotective; Neurotrophic; Parkinson's disease; Pituitary adenylate cyclase activating polypeptide

Indexed keywords

ALPHA SECRETASE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DRUG EFFECT; HUMAN; MEMORY; MEMORY DISORDER; MICROGLIA; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; NEURODEGENERATIVE DISEASES;

HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE;

EID: 84930626955     PISSN: 14258153     EISSN: 16891392     Source Type: Journal    
DOI: 10.1515/cmble-2015-0008     Document Type: Article

References (82)

1. Miyata, A., Arimura, A., Dahl, R. R., Minamino, N., Uehara, A., Jiang, L., Culler, M. D. and Coy, D. H. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 164 (1989) 567-574.
2. Vaudry, D., Falluel-Morel, A., Bourgault, S., Basille, M., Burel, D., Wurtz, O., Fournier, A., Chow, B. K., Hashimoto, H., Galas, L. and Vaudry, H. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev. 61 (2009) 283-357.
3. Arimura, A. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn. J. Physiol. 48 (1998) 301-331.
4. Nowak, J. Z. and Zawilska, J. B. PACAP in avians: origin, occurrence, and receptors-pharmacological and functional considerations. Curr. Pharm. Des. 9 (2003) 467-481.
5. Rawlings, S. R. and Hezareh, M. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Endocr. Rev. 17 (1996) 4-29.
6. Sherwood, N. M., Krueckl, S. L. and McRory, J. E. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr. Rev. 21 (2000) 619-670.
7. Miyata, A., Jiang, L., Dahl, R. D., Kitada, C., Kubo, K., Fujino, M., Minamino, N. and Arimura, A. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem. Biophys. Res. Commun. 170 (1990) 643-648.
8. Harmar, A. J., Fahrenkrug, J., Gozes, I., Laburthe, M., May, V., Pisegna, J. R., Vaudry, D., Vaudry, H., Waschek, J. A. and Said, S. I. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br. J. Pharmacol. 166 (2012) 4-17.
9. El Zein, N., Badran, B. and Sariban, E. The neuropeptide pituitary adenylate cyclase activating polypeptide modulates Ca2+ and pro-inflammatory functions in human monocytes through the G protein-coupled receptors VPAC-1 and formyl peptide receptor-like 1. Cell Calcium 43 (2008) 270-284.
10. Cattaneo, F., Parisi, M. and Ammendola, R. Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists. Int. J. Mol. Sci. 14 (2013) 7193-7230.
11. Kim, Y., Lee, B. D., Kim, O., Bae, Y. S., Lee, T., Suh, P. G. and Ryu, S. H. Pituitary adenylate cyclase-activating polypeptide 27 is a functional ligand for formyl peptide receptor-like 1. J. Immunol. 176 (2006) 2969-2975.
12. Spengler, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeburg, P. H. and Journot, L. Differential signal transduction by five splice variants of the PACAP receptor. Nature 365 (1993) 170-175.
13. Zhou, C. J., Shioda, S., Yada, T., Inagaki, N., Pleasure, S. J. and Kikuyama, S. PACAP and its receptors exert pleiotropic effects in the nervous system by activating multiple signaling pathways. Curr. Protein Pept. Sci. 3 (2002) 423-439.
14. Arimura, A., Somogyvari-Vigh, A., Miyata, A., Mizuno, K., Coy, D. H. and Kitada, C. Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 129 (1991) 2787-2789.
15. Ressler, K. J., Mercer, K. B., Bradley, B., Jovanovic, T., Mahan, A., Kerley, K., Norrholm, S. D., Kilaru, V., Smith, A. K., Myers, A. J., Ramirez, M., Engel, A., Hammack, S. E., Toufexis, D., Braas, K. M., Binder, E. B. and May, V. Posttraumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 470 (2011) 492-497.
16. Shen, S., Gehlert, D. R. and Collier, D. A. PACAP and PAC1 receptor in brain development and behavior. Neuropeptides 47 (2013) 421-430.
17. Almli, L. M., Mercer, K. B., Kerley, K., Feng, H., Bradley, B., Conneely, K. N. and Ressler, K. J. ADCYAP1R1 genotype associates with post-traumatic stress symptoms in highly traumatized African-American females. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 162B (2013) 262-272.
18. Banks, W. A., Moinuddin, A. and Morley, J. E. Regional transport of TNF-alpha across the blood-brain barrier in young ICR and young and aged SAMP8 mice. Neurobiol. Aging 22 (2001) 671-676.
19. Banks, W. A., Farr, S. A. and Morley, J. E. Permeability of the blood-brain barrier to albumin and insulin in the young and aged SAMP8 mouse. J. Gerontol. A Biol Sci. Med. Sci. 55 (2000) B601-606.
20. Moinuddin, A., Morley, J. E. and Banks, W. A. Regional variations in the transport of interleukin-1alpha across the blood-brain barrier in ICR and aging SAMP8 mice. Neuroimmunomodulation 8 (2000) 165-170.
21. Ji, R., Tian, S., Lu, H. J., Lu, Q., Zheng, Y., Wang, X., Ding, J., Li, Q. and Lu, Q. TAM receptors affect adult brain neurogenesis by negative regulation of microglial cell activation. J. Immunology 191 (2013) 6165-6177.
22. Banks, W. A. Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr. Pharm. Des. 11 (2005) 973-984.
23. Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U. and Fehm, H. L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 5 (2002) 514-516.
24. Lochhead, J. J. and Thorne, R. G. Intranasal delivery of biologics to the central nervous system. Adv. Drug. Deliv. Rev. 64 (2012) 614-628.
25. Banks, W. A., Kastin, A. J., Komaki, G. and Arimura, A. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. J. Pharmacol. Exp. Ther. 267 (1993) 690-696.
26. Somogyvari-Vigh, A., Pan, W., Reglodi, D., Kastin, A. J. and Arimura, A. Effect of middle cerebral artery occlusion on the passage of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier in the rat. Regul. Pept. 91 (2000) 89-95.
27. Yan, X. B., Wang, S. S., Hou, H.-L., Ji, R. and Zhou, J. N. Lithium improves the behavioral disorder in rats subjected to transient global cerebral ischemia. Behav. Brain Res. 177 (2007) 282-289.
28. Ji, R., Meng, L. and Yang, R. Neuroprotective effects of pituitary adenylate cyclase-activating polypeptide. Int. J. Adv. Innovat. Thoughts Ideas 3 (2014) 112.
29. Cipriani, G., Dolciotti, C., Picchi, L. and Bonuccelli, U. Alzheimer and his disease: a brief history. Neurol. Sci. 32 (2011) 275-279.
30. Thies, W. and Bleiler, L. Alzheimer's disease facts and figures. Alzheimers Dement. 9 (2013) 208-245.
31. Brookmeyer, R., Johnson, E., Ziegler-Graham, K. and Arrighi, H. M. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 3 (2007) 186-191.
32. Dubois, B., Feldman, H. H., Jacova, C., Dekosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., Meguro, K., O'Brien, J., Pasquier, F., Robert, P., Rossor, M., Salloway, S., Stern, Y., Visser, P. J. and Scheltens, P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6 (2007) 734-746.
33. Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D. and Jones, E. Alzheimer's disease. Lancet 377 (2011) 1019-1031.
34. Francis, P. T., Palmer, A. M., Snape, M. and Wilcock, G. K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 66 (1999) 137-147.
35. Takei, N., Torres, E., Yuhara, A., Jongsma, H., Otto, C., Korhonen, L., Abiru, Y., Skoglosa, Y., Schutz, G., Hatanaka, H., Sofroniew, M. V. and Lindholm, D. Pituitary adenylate cyclase-activating polypeptide promotes the survival of basal forebrain cholinergic neurons in vitro and in vivo: comparison with effects of nerve growth factor. Eur. J. Neurosci. 12 (2000) 2273-2280.
36. Yuhara, A., Ishii, K., Nishio, C., Abiru, Y., Yamada, M., Nawa, H., Hatanaka, H. and Takei, N. PACAP and NGF cooperatively enhance choline acetyltransferase activity in postnatal basal forebrain neurons by complementary induction of its different mRNA species. Biochem. Biophys. Res. Commun. 301 (2003) 344-349.
37. Ji, R., Liu, F., Meng, L. and Chen, X. Structures and biosynthesis of enediyne natural products. Int. J. Adv. Innovat. Thoughts Ideas 3 (2014) 110.
38. Hardy, J. and Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12 (1991) 383-388.
39. Mudher, A. and Lovestone, S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci. 25 (2002) 22-26.
40. Hardy, J. and Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356.
41. Mattson, M. P., Cheng, B., Culwell, A. R., Esch, F. S., Lieberburg, I. and Rydel, R. E. Evidence for excitoprotective and intraneuronal calciumregulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10 (1993) 243-254.
42. Caille, I., Allinquant, B., Dupont, E., Bouillot, C., Langer, A., Muller, U. and Prochiantz, A. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development 131 (2004) 2173-2181.
43. Lannfelt, L., Basun, H., Wahlund, L. O., Rowe, B. A. and Wagner, S. L. Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Nat. Med. (1995) 829-832.
44. Sennvik, K., Fastbom, J., Blomberg, M., Wahlund, L. O., Winblad, B. and Benedikz, E. Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 278 (2000) 169-172.
45. Taylor, C. J., Ireland, D. R., Ballagh, I., Bourne, K., Marechal, N. M., Turner, P. R., Bilkey, D. K., Tate, W. P. and Abraham, W. C. Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Neurobiol. Dis. 31 (2008) 250-260.
46. Ishida, A., Furukawa, K., Keller, J. N. and Mattson, M. P. Secreted form of beta-amyloid precursor protein shifts the frequency dependency for induction of LTD, and enhances LTP in hippocampal slices. Neuroreport 8 (1997) 2133-2137.
47. Onoue, S., Endo, K., Ohshima, K., Yajima, T. and Kashimoto, K. The neuropeptide PACAP attenuates beta-amyloid (1-42)-induced toxicity in PC12 cells. Peptides 23 (2002) 1471-1478.
48. Kojro, E., Postina, R., Buro, C., Meiringer, C., Gehrig-Burger, K. and Fahrenholz, F. The neuropeptide PACAP promotes the alpha-secretase pathway for processing the Alzheimer amyloid precursor protein. FASEB J. 20 (2006) 512-514.
49. Wu, Z. L., Ciallella, J. R., Flood, D. G., O'Kane, T. M., Bozyczko-Coyne, D. and Savage, M. J. Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease. Neurobiol. Aging 27 (2006) 377-386.
50. Han, P., Tang, Z., Yin, J., Maalouf, M., Beach, T. G., Reiman, E. M. and Shi, J. Pituitary adenylate cyclase-activating polypeptide protects against betaamyloid toxicity. Neurobiol. Aging 35 (2014) 2064-2071.
51. Rat, D., Schmitt, U., Tippmann, F., Dewachter, I., Theunis, C., Wieczerzak, E., Postina, R., van Leuven, F., Fahrenholz, F. and Kojro, E. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 25 (2011) 3208-3218.
52. Pohanka, M. Alzheimer s disease and oxidative stress: a review. Curr. Med. Chem. 21 (2013) 356-364.
53. Vaudry, D., Pamantung, T. F., Basille, M., Rousselle, C., Fournier, A., Vaudry, H., Beauvillain, J. C. and Gonzalez, B. J. PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. Eur. J. Neurosci. 15 (2002) 1451-1460.
54. Heneka, M. T., Nadrigny, F., Regen, T., Martinez-Hernandez, A., Dumitrescu-Ozimek, L., Terwel, D., Jardanhazi-Kurutz, D., Walter, J., Kirchhoff, F., Hanisch, U. K. and Kummer, M. P. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 6058-6063.
55. De Lau, L. M. and Breteler, M. M. Epidemiology of Parkinson's disease. Lancet Neurol. 5 (2006) 525-535.
56. Gelb, D. J., Oliver, E. and Gilman, S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56 (1999) 33-39.
57. Jankovic, J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79 (2008) 368-376.
58. McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., Aarsland, D., Arai, H., Ballard, C. G., Boeve, B., Burn, D. J., Costa, D., Del Ser, T., Dubois, B., Galasko, D., Gauthier, S., Goetz, C. G., Gomez-Tortosa, E., Halliday, G., Hansen, L. A., Hardy, J., Iwatsubo, T., Kalaria, R. N., Kaufer, D., Kenny, R. A., Korczyn, A., Kosaka, K., Lee, V. M., Lees, A., Litvan, I., Londos, E., Lopez, O. L., Minoshima, S., Mizuno, Y., Molina, J. A., Mukaetova-Ladinska, E. B., Pasquier, F., Perry, R. H., Schulz, J. B., Trojanowski, J. Q., Yamada, M. and Consortiumon, D. L. B. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 (2005) 1863-1872.
59. Forte, G., Bocca, B., Senofonte, O., Petrucci, F., Brusa, L., Stanzione, P., Zannino, S., Violante, N., Alimonti, A. and Sancesario, G. Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson's disease. J. Neural. Transm. 111 (2004) 1031-1040.
60. Witholt, R., Gwiazda, R. H. and Smith, D. R. The neurobehavioral effects of subchronic manganese exposure in the presence and absence of preparkinsonism. Neurotoxicol. Teratol. 22 (2000) 851-861.
61. Matusch, A., Depboylu, C., Palm, C., Wu, B., Hoglinger, G. U., Schafer, M. K. and Becker, J. S. Cerebral bioimaging of Cu, Fe, Zn, and Mn in the MPTP mouse model of Parkinson's disease using laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). J. Am. Soc. Mass Spectrom. 21 (2010) 161-171.
62. Goldman, S. M. Environmental toxins and Parkinson's disease. Annu. Rev. Pharmacol. Toxicol. 54 (2014) 141-164.
63. Chin, M. H., Qian, W. J., Wang, H., Petyuk, V. A., Bloom, J. S., Sforza, D. M., Lacan, G., Liu, D., Khan, A. H., Cantor, R. M., Bigelow, D. J., Melega, W. P., Camp, D. G., 2nd, Smith, R. D. and Smith, D. J. Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson's disease. J. Proteome Res. 7 (2008) 666-677.
64. Gerlach, M. and Riederer, P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural Transm. 103 (1996) 987-1041.
65. Lotharius, J. and Brundin, P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3 (2002) 932-942.
66. Deumens, R., Blokland, A. and Prickaerts, J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 175 (2002) 303-317.
67. Ito, Y., Arakawa, M., Ishige, K. and Fukuda, H. Comparative study of survival signal withdrawal- and 4-hydroxynonenal-induced cell death in cerebellar granule cells. Neurosci. Res. 35 (1999) 321-327.
68. Vaudry, D., Rousselle, C., Basille, M., Falluel-Morel, A., Pamantung, T. F., Fontaine, M., Fournier, A., Vaudry, H. and Gonzalez, B. J. Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 6398-6403.
69. Falluel-Morel, A., Vaudry, D., Aubert, N., Galas, L., Benard, M., Basille, M., Fontaine, M., Fournier, A., Vaudry, H. and Gonzalez, B. J. Pituitary adenylate cyclase-activating polypeptide prevents the effects of ceramides on migration, neurite outgrowth, and cytoskeleton remodeling. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2637-2642.
70. Meng, L., Chen, X., Yang, R. and Ji, R. Role of BDNF in the taste system. Front. Biol. 9 (2014) 481-488.
71. Wang, G., Qi, C., Fan, G. H., Zhou, H. Y. and Chen, S. D. PACAP protects neuronal differentiated PC12 cells against the neurotoxicity induced by a mitochondrial complex I inhibitor, rotenone. FEBS Lett. 579 (2005) 4005-4011.
72. Brown, D., Tamas, A., Reglodi, D. and Tizabi, Y. PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease. J. Mol. Neurosci. 50 (2013) 600-607.
73. Reglodi, D., Tamas, A., Lubics, A., Szalontay, L. and Lengvari, I. Morphological and functional effects of PACAP in 6-hydroxydopamineinduced lesion of the substantia nigra in rats. Regul. Pept. 123 (2004) 85-94.
74. Reglodi, D., Lubics, A., Tamas, A., Szalontay, L. and Lengvari, I. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease. Behav. Brain Res. 151 (2004) 303-312.
75. Wang, G., Pan, J., Tan, Y. Y., Sun, X. K., Zhang, Y. F., Zhou, H. Y., Ren, R. J., Wang, X. J. and Chen, S. D. Neuroprotective effects of PACAP27 in mice model of Parkinson's disease involved in the modulation of K (ATP) subunits and D2 receptors in the striatum. Neuropeptides 42 (2008) 267-276.
76. McGeer, P. L. and McGeer, E. G. Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis. Assoc. Disord. 12 Suppl 2 (1998) S1-6.
77. Sriram, K., Matheson, J. M., Benkovic, S. A., Miller, D. B., Luster, M. I. and O'Callaghan, J. P Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. 16 (2002) 1474-1476.
78. Aloisi, F. The role of microglia and astrocytes in CNS immune surveillance and immunopathology. Adv. Exp. Med. Biol. 468 (1999) 123-133.
79. Meng, L., Jiang, X. and Ji, R. Role of IL6 and TNFα in hippocampal neurogenesis of TAM triple knockout mice. Int. J. Adv. Innovat. Thoughts Ideas 3 (2014) 109.
80. Chen, X., Ji, R, Jiang, X., Yang, R, Liu, F. and Xin, Y Iterative type I polyketide synthases involved in enediyne natural product biosynthesis. Iubmb Life 66 (2014) 587-595.
81. Jenner, P. and Olanow, C. W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 (1996) S161-170.
82. Yang, S., Yang, J., Yang, Z., Chen, P., Fraser, A., Zhang, W, Pang, H., Gao, X., Wilson, B., Hong, J. S. and Block, M. L. Pituitary adenylate cyclaseactivating polypeptide (PACAP) 38 and PACAP4-6 are neuroprotective through inhibition of NADPH oxidase: potent regulators of microgliamediated oxidative stress. J. Pharmacol. Exp. Ther. 319 (2006) 595-603.